Sanofi $SNY Stock Holdings Lowered by Zions Bancorporation National Association UT

Zions Bancorporation National Association UT cut its holdings in shares of Sanofi (NASDAQ:SNY) by 33.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 136,975 shares of the company’s stock after selling 69,047 shares during the period. Zions Bancorporation National Association UT’s holdings in Sanofi were worth $6,465,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in SNY. Caprock Group LLC acquired a new position in shares of Sanofi in the 3rd quarter valued at about $1,347,000. Assetmark Inc. boosted its stake in shares of Sanofi by 25.0% during the 3rd quarter. Assetmark Inc. now owns 357,172 shares of the company’s stock valued at $16,859,000 after buying an additional 71,356 shares during the period. Thrivent Financial for Lutherans raised its holdings in shares of Sanofi by 10,152.1% during the third quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company’s stock worth $103,846,000 after acquiring an additional 2,178,647 shares in the last quarter. Willis Investment Counsel boosted its position in Sanofi by 11.3% during the third quarter. Willis Investment Counsel now owns 556,700 shares of the company’s stock valued at $26,276,000 after purchasing an additional 56,500 shares during the last quarter. Finally, Hantz Financial Services Inc. grew its stake in Sanofi by 43.1% in the third quarter. Hantz Financial Services Inc. now owns 80,832 shares of the company’s stock valued at $3,815,000 after purchasing an additional 24,328 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on SNY. HSBC reissued a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Bank of America downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday. Citigroup assumed coverage on Sanofi in a research note on Tuesday, January 27th. They set a “neutral” rating for the company. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. Five research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Sanofi presently has an average rating of “Hold” and a consensus price target of $62.67.

Sanofi News Roundup

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Closed Dynavax acquisition bolsters Sanofi’s adult vaccine portfolio — a strategic, revenue‑adding move that supports longer‑term vaccine growth. Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi issued official press materials confirming Belén Garijo will become CEO after the board decided not to renew Paul Hudson’s mandate — a formal transition that reduces short‑term uncertainty about leadership succession. Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
• Neutral Sentiment: Profiles and coverage detail Garijo’s background (ex‑Merck KGaA) and the board’s decision — helpful context for assessing whether she can execute a turnaround. Who is Sanofi’s new CEO Belén Garijo?
• Negative Sentiment: Market reaction: multiple outlets report a sell‑off and the stock trading near 52‑week lows as investors worry the leadership change reflects deeper pipeline and execution problems. Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
• Negative Sentiment: Analyst reaction: Bank of America downgraded Sanofi from Buy to Neutral, increasing near‑term downside pressure from institutional holders. Sanofi downgraded by Bank of America
• Negative Sentiment: Investor concerns about the drug pipeline and U.S. vaccine sentiment under the current administration add execution risk for the incoming CEO — Reuters highlights that Garijo must accelerate R&D and navigate political headwinds. Sanofi’s new CEO needs to fix drug pipeline and navigate Trump
• Negative Sentiment: News summaries and headlines emphasize the abrupt ousting of Paul Hudson, which has amplified investor uncertainty and short‑term selling. SNY Stock Falls After Board Suddenly Makes Leadership Change

Sanofi Trading Down 2.2%

Shares of Sanofi stock opened at $46.01 on Monday. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The company’s fifty day simple moving average is $47.73 and its 200-day simple moving average is $48.59. The company has a market cap of $112.22 billion, a price-to-earnings ratio of 12.78, a PEG ratio of 1.20 and a beta of 0.45. The company has a current ratio of 1.09, a quick ratio of 0.29 and a debt-to-equity ratio of 0.20.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.